Tripathy D. Lichinitzer M. Lazarev A. MacLachlan S.A. Apffelstaedt J. Budde M. Bergstrom B. Abdi E. Abramson N. Baker T.M. Kirkegaard L.W. Schmidt J.R. Bell D. Bell R. Belt R.J. Bernstein J.I. Just R.G. Burningham R.A. Trafficante B. Caggiano V. Cartwright T. Chernozemsky I.N. Clingan P. Conkling P. Craig J.B. Grosbach A.B. Decker D. Dickman E. Dugan Jr. W. Dunlap W. Eisenberg P.D. Ellerton J. Ettinger M. Ey F. Falkson G. Falkson C. Fink K. Fleagle J. Forlenza T. Gorbunova V.A. Gross G.E. Grotes T. Grygiel J. Gudgeon A. Werner I.D. Hacking D. Harrer G.W. Harvey V. Hirsch R. Koletsky A. Jordaan J.P. Cash D.K. Khasanov R.Sh. LaFata J.A. LaFollette S. Koshla P. Landers G. Lebos H.C. Wade J.L. Lowenthal T. Lyons R. McLachlan S.-A. Murray R. Perez D. Phadke K. Rapoport B. Rausch P.G. Robinson B. Sarna G. Saven A. Schwartz M. Semiglazov V.F. Stewart J. Sunderland K. Thomas L. Vogel C.L. Martinez-Rio M. Vorobiof D.A. Wilks S. Woolley P.
(2004)
Background: We report the first results of a randomized trial assessing a new oral aminobisphosphonate, ibandronate, in patients with bone metastases from breast cancer. Patients and methods: Patients (n = 435) received ...